Gold J, Cullinane S, Chen J, Seo S, Oz M C, Oliver J A, Landry D W
Department of Medicine, Columbia University, College of Physicians & Surgeons, New York, New York, USA.
Am J Cardiol. 2000 Feb 15;85(4):506-8, A11. doi: 10.1016/s0002-9149(99)00783-3.
The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension. In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.
诸如米力农等磷酸二酯酶抑制剂在治疗严重心力衰竭时的应用常常受到限制,因为它们会引起血管舒张和低血压。在用米力农治疗后出现低血压的失代偿性心力衰竭患者中,低剂量血管加压素可恢复血压,且不抑制米力农的正性肌力作用。